🇺🇸 FDA
Patent

US 10738305

Materials and methods for treatment of hemoglobinopathies

granted A61KA61K35/28A61K35/545

Quick answer

US patent 10738305 (Materials and methods for treatment of hemoglobinopathies) held by Vertex Pharmaceuticals Incorporated expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K35/28, A61K35/545, A61K38/42, A61K48/00